ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma ...
US biotech ImmunityBio has reported two ongoing complete remissions lasting seven and 15 months in patients with Waldenstrom ...
Saudi Gazette on MSN
Saudi: SFDA approves registration of 'Anktiva' for treatment of bladder and lung cancer
The SFDA is the first regulatory authority globally to grant conditional approval for this medication for the treatment of NSCLC ...
Even world-leading happiness experts are vulnerable to Blue Monday. The third Monday in January, which lands on the 19th this ...
Cell therapies, often described as ‘living therapies’, are transforming cancer treatment. These drugs harness the power of the immune system to deliver remarkable results, particularly for blood ...
Discover Parks & Wildlife on MSN
14 proven health perks park explorers say you can’t replicate at home
Most of us visit national parks for the incredible scenery or the chance to spot wildlife in its natural habitat. We plan our ...
11hon MSN
A new nanorobot designed to improve immune cell recognition could help treat colorectal cancer
Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback